ClinicalTrials.gg
CompletedNCT03474042PELICANUpdated Jun 11, 2018

GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

A Phase 2 interventional study of GLPG2737 and Placebo in Cystic Fibrosis, sponsored by Galapagos NV. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-11.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2017, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies in Cystic Fibrosis with a site in Germany — 9 open to participants now, 14 under way, 5 of them phase 3. Cystic Fibrosis · Germany.

Enrollment
111th of 126
22 · median 103
Started
2017
with 13 others
Phase 2
37 of 147
1 open now
Registered
95th of 147
by date
Lead sponsor
4 of 147
Galapagos NV

Among the 147 studies in Cystic Fibrosis with a site in Germany, this one is the 111th largest by enrollment of the 126 interventional ones that give a count, is one of 14 that started in 2017, is one of 37 in phase 2, and was the 95th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

9 of the 147 studies in Cystic Fibrosis with a site in Germany are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Cystic Fibrosis with a site in Germany, or all of them as a file.
02

Study summary

This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate GLPG2737 administered orally b.i.d. for 28 days to adult male and female subjects with a confirmed diagnosis of cystic fibrosis homozygous for the F508del CFTR mutation and on stable treatment with Orkambi.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject ≥18 years of age on the day of signing the ICF.
  • A confirmed clinical diagnosis of CF and homozygous for the F508del CFTR mutation.
  • Stable intake of physician prescribed Orkambi (lumacaftor 400 mg/ivacaftor 250 mg b.i.d.) for at least 12 weeks prior to the first study drug administration, and planned continuation of Orkambi for the duration of the study.
  • ≥40% of predicted normal for age, gender and height at screening (pre- or postbronchodilator).
  • Sweat chloride concentration ≥60 mmol/L at screening.

Exclusion criteria

Exclusion Criteria:

  • History of serious allergic reaction to any drug as determined by the investigator (e.g., anaphylaxis requiring hospitalization) and/or known sensitivity to any component of the study drug.
  • History of unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.
  • Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 4 weeks prior to the first study drug administration.
  • History of hepatic cirrhosis with portal hypertension (e.g.,signs/symptoms of splenomegaly, esophageal varices, etc.).
  • Abnormal liver function test at screening, defined as (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or gammaglutamyl transferase (GGT) ≥3 x the (ULN), and/or total ≥1.5 x the ULN at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    GLPG2737

    GLPG2737 will be provided as capsules for oral use.

    Drug: GLPG2737

  • Placebo comparator
    Placebo

    Placebo will be provided as capsules for oral use.

    Drug: Placebo

Interventions

  • GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.

  • DrugPlacebo

    Placebo oral capsules administered twice daily for 28 days on top of Orkambi.

06

What researchers measure

Primary outcomes

  1. Change from baseline in sweat chloride concentration compared to placebo

    To assess Change from baseline in sweat chloride concentration compared to placebo.

    Time frame: Between day 1 pre-morning dose and Day 28.

Secondary outcomes

  1. Change versus placebo in the proportion of subjects with adverse events.

    To assess safety and tolerability by the number and percentage of subjects with adverse events.

    Time frame: Between Day 1 and 3 weeks after the last dose.

  2. Change from baseline in sweat chloride concentration.

    To assess the change from baseline in sweat chloride concentration.

    Time frame: From baseline (pre-morning dose on Day 1) through 28 days.

  3. Change in percent predicted forced expiratory volume in 1 second (FEV1).

    To assess the change from baseline in percent predicted forced expiratory volume in 1 second (FEV1).

    Time frame: From baseline (pre-morning dose on Day 1) through 28 days.

  4. Change in the respiratory domain of the cystic fibrosis questionnaire-revised (CFQ-R).

    To assess the change from baseline in the respiratory domain of the cystic fibrosis questionnaire-revised (CFQ-R).

    Time frame: From baseline (pre-morning dose on Day 1) through 28 days.

  5. Maximum observed plasma concentration of GLPG2737 (Cmax)

    To characterize the PK of GLPG2737 and its active metabolite, ivacaftor, and lumacaftor.

    Time frame: Between day 1 pre-dose and day 14.

  6. Area under the plasma concentration-time curve from time zero until 8 hours (AUC0-8h) post-dose calculated by the linear up - logarithmic down trapezoidal rule (on Day 14)

    To characterize the PK of GLPG2737 and its active metabolite G1125498 (M4), ivacaftor, and lumacaftor.

    Time frame: Between day 1 pre-dose and day 14.

  7. Trough plasma concentration observed at the end of the dosing interval (Ctrough).

    To characterize the PK of GLPG2737 and its active metabolite G1125498 (M4), ivacaftor, and lumacaftor.

    Time frame: Between day 1 pre-dose and day 28.

07

Study locations

9 sites
  • Study Site II
    Berlin, Germany
  • Study Site X
    Dresden, Germany
  • Study Site III
    Essen, Germany
  • Study Site IV
    Frankfurt, Germany
  • Study Site I
    Heidelberg, Germany
  • Study Site V
    Köln, Germany
  • Study Site VI
    München, Germany
  • Study Site IX
    Stuttgart, Germany
  • Study Site VIII
    Tübingen, Germany
08

References and documents

Publications

  • van Koningsbruggen-Rietschel S, Conrath K, Fischer R, Sutharsan S, Kempa A, Gleiber W, Schwarz C, Hector A, Van Osselaer N, Pano A, Corveleyn S, Bwirire D, Santermans E, Muller K, Bellaire S, Van de Steen O. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). J Cyst Fibros. 2020 Mar;19(2):292-298. doi: 10.1016/j.jcf.2019.09.006. Epub 2019 Oct 5. PubMed 31594690 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Apr 2018, 4 months.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 4 months is below that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2018
First posted
Mar 22, 2018
StartActual
Nov 29, 2017
Primary completionActual
Apr 10, 2018
CompletionActual
Apr 10, 2018
Last update
Jun 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03474042
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Mar 22, 2018
Start date
Nov 29, 2017
Primary completion
Apr 10, 2018
Completion
Apr 10, 2018
Last update
Jun 11, 2018

Study contacts

Olivier Van de Steen, MD MBA
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG-2737

Start the discussion